Analysts Anticipate Jounce Therapeutics Inc (JNCE) to Post -$0.59 Earnings Per Share

Analysts expect that Jounce Therapeutics Inc (NASDAQ:JNCE) will post earnings of ($0.59) per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Jounce Therapeutics’ earnings. The lowest EPS estimate is ($1.04) and the highest is ($0.22). Jounce Therapeutics posted earnings per share of $0.05 during the same quarter last year, which would indicate a negative year-over-year growth rate of 1,280%. The company is scheduled to report its next quarterly earnings report on Friday, March 9th.

According to Zacks, analysts expect that Jounce Therapeutics will report full-year earnings of ($0.86) per share for the current financial year, with EPS estimates ranging from ($1.29) to ($0.49). For the next fiscal year, analysts forecast that the firm will report earnings of ($1.37) per share, with EPS estimates ranging from ($1.58) to ($1.15). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Jounce Therapeutics.

Jounce Therapeutics (NASDAQ:JNCE) last announced its quarterly earnings results on Monday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.12. Jounce Therapeutics had a negative return on equity of 1.39% and a negative net margin of 2.03%. The company had revenue of $18.10 million during the quarter, compared to analyst estimates of $20.00 million. The company’s revenue for the quarter was up 7.1% compared to the same quarter last year.

A number of research analysts have issued reports on the company. J P Morgan Chase & Co set a $28.00 price target on Jounce Therapeutics and gave the stock a “buy” rating in a research report on Monday, November 13th. Robert W. Baird restated an “outperform” rating and issued a $30.00 price objective on shares of Jounce Therapeutics in a report on Monday, September 18th. Finally, Zacks Investment Research upgraded Jounce Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 15th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $23.67.

Jounce Therapeutics (JNCE) opened at $14.14 on Friday. Jounce Therapeutics has a 12-month low of $11.05 and a 12-month high of $29.29.

Several institutional investors have recently made changes to their positions in JNCE. TIAA CREF Investment Management LLC acquired a new stake in shares of Jounce Therapeutics in the first quarter valued at $229,000. Geode Capital Management LLC acquired a new stake in shares of Jounce Therapeutics during the first quarter worth $1,573,000. Goldman Sachs Group Inc. acquired a new stake in shares of Jounce Therapeutics during the first quarter worth $271,000. Strs Ohio raised its position in shares of Jounce Therapeutics by 1,863.2% during the second quarter. Strs Ohio now owns 37,300 shares of the company’s stock worth $523,000 after purchasing an additional 35,400 shares during the period. Finally, Schwab Charles Investment Management Inc. raised its position in shares of Jounce Therapeutics by 95.5% during the second quarter. Schwab Charles Investment Management Inc. now owns 24,219 shares of the company’s stock worth $340,000 after purchasing an additional 11,833 shares during the period. Institutional investors and hedge funds own 47.55% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://www.com-unik.info/2017/12/10/analysts-anticipate-jounce-therapeutics-inc-jnce-to-post-0-59-earnings-per-share.html.

About Jounce Therapeutics

Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.

Get a free copy of the Zacks research report on Jounce Therapeutics (JNCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about Jounce Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Jounce Therapeutics Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit